{"entity":{"id":"a2-biotherapeutics","kind":"company","name":"A2 Biotherapeutics","aka":["A2 Bio"],"tldr":"A2 Biotherapeutics is a US-based cell therapy company that leads 3 cancer trials in OnCo, testing the logic-gated CAR-T therapies A2B395, A2B530, A2B694 and A2B543 in colorectal cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma and renal cell carcinoma.","summary":"A2 Biotherapeutics is a clinical-stage biotechnology company developing logic-gated CAR T-cell therapies on its Tmod platform, designed to distinguish tumour cells from normal cells. Its clinical programmes include A2B395 (EGFR), A2B694 and A2B543 (mesothelin) and A2B530 (CEA). On ClinicalTrials.gov it is the lead sponsor of 3 trials recorded in OnCo: NCT06682793 (phase 1/2, A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T,...), NCT05736731 (phase 1/2, A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Particip...) and NCT06051695 (phase 1/2, A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T,...). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://www.a2bio.com"},{"label":"ClinicalTrials.gov: trials led by A2 Biotherapeutics","url":"https://clinicaltrials.gov/search?lead=A2%20Biotherapeutics%20Inc."}],"tags":["ctgov-sponsor"],"related":[],"cancers":["colorectal","nsclc","head-and-neck","rcc","tnbc","pancreatic","ovarian","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06682793","nct05736731","nct06051695"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Agoura Hills, California","country":"US","companyType":"cell-therapy","website":"https://www.a2bio.com","stage":"growth","investors":[],"funding":[]},"route":"/companies/a2-biotherapeutics/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"rcc","kind":"cancer","name":"Renal cell carcinoma","route":"/cancers/rcc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"trial":[{"id":"nct06682793","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","route":"/trials/nct06682793/"},{"id":"nct05736731","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression","route":"/trials/nct05736731/"},{"id":"nct06051695","kind":"trial","name":"A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","route":"/trials/nct06051695/"}]}}